<DOC>
	<DOCNO>NCT00569114</DOCNO>
	<brief_summary>This multicenter , open-label , phase 1 , dose escalation study . The purpose determine high dose TG01 safely give patient Non-Small Cell Lung Cancer combination erlotinib .</brief_summary>
	<brief_title>Phase 1 Study TG01 Erlotinib Non-small Cell Lung Cancer ( NCSLC ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria ( include limit ) : Histogically pathologically determine relapsed/recurrent Stage IIIb ( plueral effusion ) IV NSCLC . Measurable evaluable disease define RECIST Must fail least one prior chemotherapy regimen refuse chemotherapy . ECOG perfromance status 0,1 , 2 . Exclusion Criteria ( include limit ) : Radiation therapy ( exclude CNS therapy ) &lt; 2 week , chemotherapy , noncytotoxic investigational agent high dose corticosteroid within 3 week intitating therpy patient recover adverse effect due agent administer 3 week earlier . Evidence New York Heart Associatation Class III great cardiac disease . History myocardial infarction , stroke , cardiovascular intervention within last 12 month . Patients antiplatlet drug anticoagulant Placix Coumadin . Systemic central nervous system metastasis . The patient must stable radiotherapy &gt; /= 2 week corticosteroid &gt; /= 1 week . Pregnant nursing woman . Patients primarily refactory erlotinib .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>